127 related articles for article (PubMed ID: 36646187)
1. In silico analysis reveals PRDX4 as a prognostic and oncogenic marker in renal papillary cell carcinoma.
Kocatürk B
Gene; 2023 Apr; 859():147201. PubMed ID: 36646187
[TBL] [Abstract][Full Text] [Related]
2. Bioinformatic analysis highlights SNHG6 as a putative prognostic biomarker for kidney renal papillary cell carcinoma.
Liu Y; Cheng X; Xi P; Zhang Z; Sun T; Gong B
BMC Urol; 2023 Apr; 23(1):54. PubMed ID: 37004005
[TBL] [Abstract][Full Text] [Related]
3. The Association of Peroxiredoxin 4 with the Initiation and Progression of Hepatocellular Carcinoma.
Guo X; Noguchi H; Ishii N; Homma T; Hamada T; Hiraki T; Zhang J; Matsuo K; Yokoyama S; Ishibashi H; Fukushige T; Kanekura T; Fujii J; Uramoto H; Tanimoto A; Yamada S
Antioxid Redox Signal; 2019 Apr; 30(10):1271-1284. PubMed ID: 29687726
[TBL] [Abstract][Full Text] [Related]
4. Oxidation of peroxiredoxin-4 induces oligomerization and promotes interaction with proteins governing protein folding and endoplasmic reticulum stress.
Elko EA; Manuel AM; White S; Zito E; van der Vliet A; Anathy V; Janssen-Heininger YMW
J Biol Chem; 2021; 296():100665. PubMed ID: 33895140
[TBL] [Abstract][Full Text] [Related]
5. Exploring the role of PRDX4 in the development of uterine corpus endometrial carcinoma.
Lei P; Yu L; Sun X; Hao J; Shi W; Sun H; Guo X; Jia X; Liu T; Zhang DL; Li L; Wang H; Xu C
Med Oncol; 2024 Jan; 41(2):48. PubMed ID: 38177789
[TBL] [Abstract][Full Text] [Related]
6. Construction autophagy-related prognostic risk signature combined with clinicopathological validation analysis for survival prediction of kidney renal papillary cell carcinoma patients.
Fei H; Chen S; Xu C
BMC Cancer; 2021 Apr; 21(1):411. PubMed ID: 33858375
[TBL] [Abstract][Full Text] [Related]
7. An
Fu S; Gong B; Ding Y; Zhuang C; Chen Q; Wang S; Li Z; Ma M; Liu Y; Zhang Z; Sun T
Comb Chem High Throughput Screen; 2022; 25(13):2278-2294. PubMed ID: 35293292
[TBL] [Abstract][Full Text] [Related]
8. PYCR in Kidney Renal Papillary Cell Carcinoma: Expression, Prognosis, Gene Regulation Network, and Regulation Targets.
Shao Z; Lu L; Cui Y; Deng L; Xu Q; Liang Q; Lu X; Zhang J; Chen J; Situ Y
Front Biosci (Landmark Ed); 2022 Dec; 27(12):336. PubMed ID: 36624948
[TBL] [Abstract][Full Text] [Related]
9. Peroxiredoxin-4 and Dopamine D5 Receptor Interact to Reduce Oxidative Stress and Inflammation in the Kidney.
Amatya B; Yang S; Yu P; Vaz de Castro PAS; Armando I; Zeng C; Felder RA; Asico LD; Jose PA; Lee H
Antioxid Redox Signal; 2023 Jun; 38(16-18):1150-1166. PubMed ID: 36401517
[No Abstract] [Full Text] [Related]
10. High PAQR4 mRNA Expression May Play a Key Role in Prognosis of Kidney Renal Papillary Cell Carcinoma.
Liu C; Cai W; Tang P; Li C
Ann Clin Lab Sci; 2023 Sep; 53(5):701-711. PubMed ID: 37945022
[TBL] [Abstract][Full Text] [Related]
11. Protective Effects of Peroxiredoxin 4 (PRDX4) on Cholestatic Liver Injury.
Zhang J; Guo X; Hamada T; Yokoyama S; Nakamura Y; Zheng J; Kurose N; Ishigaki Y; Uramoto H; Tanimoto A; Yamada S
Int J Mol Sci; 2018 Aug; 19(9):. PubMed ID: 30149550
[TBL] [Abstract][Full Text] [Related]
12. Multidimensional Analyses of Tumor Immune Microenvironment Reveal the Possible Rationality of Immunotherapy and Identify High Immunotherapy Response Subtypes for Renal Papillary Cell Carcinoma.
Wei B; Yu M; Yao J; Jiang M; An J; Yang J; Lin J; Zhao Y; Zhu Y
Front Immunol; 2021; 12():657951. PubMed ID: 34531849
[TBL] [Abstract][Full Text] [Related]
13. Peroxiredoxin 4 suppresses anoikis and augments growth and metastasis of hepatocellular carcinoma cells through the β-catenin/ID2 pathway.
Wang W; Shen XB; Huang DB; Jia W; Liu WB; He YF
Cell Oncol (Dordr); 2019 Dec; 42(6):769-781. PubMed ID: 31256347
[TBL] [Abstract][Full Text] [Related]
14. Comprehensive analysis of the expression levels and prognostic values of PRDX family genes in glioma.
Szeliga M
Neurochem Int; 2022 Feb; 153():105256. PubMed ID: 34968631
[TBL] [Abstract][Full Text] [Related]
15. New insights into the roles of peroxiredoxins in cancer.
Liu Y; Wang P; Hu W; Chen D
Biomed Pharmacother; 2023 Aug; 164():114896. PubMed ID: 37210897
[TBL] [Abstract][Full Text] [Related]
16. System analysis of
Situ Y; Xu Q; Deng L; Zhu Y; Gao R; Lei L; Shao Z
Int J Biol Markers; 2022 Mar; 37(1):90-101. PubMed ID: 34870494
[TBL] [Abstract][Full Text] [Related]
17. Comprehensive analysis of
Bai J; Zheng A; Ha Y; Xu X; Yu Y; Lu Y; Zheng S; Shen Z; Luo B; Jie W
Front Mol Biosci; 2022; 9():988777. PubMed ID: 36188228
[No Abstract] [Full Text] [Related]
18. Interplay Between Mitochondrial Peroxiredoxins and ROS in Cancer Development and Progression.
Ismail T; Kim Y; Lee H; Lee DS; Lee HS
Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31500275
[TBL] [Abstract][Full Text] [Related]
19. Peroxiredoxin 4, a new favorable regulator, can protect oocytes against oxidative stress damage during in vitro maturation.
Qian Y; Zou X; Liang X; Lu N; Cui Y; Liu J; Meng Y
Biochem Biophys Res Commun; 2022 Apr; 601():52-58. PubMed ID: 35228121
[TBL] [Abstract][Full Text] [Related]
20. [New early gastric cancer marker PRDX4 promote the tumorigenesis and progression of gastric cancer via eliminating ROS].
Jia R; Shi D; Li W; Yang J; Zhang Y; Han Y
Sheng Wu Gong Cheng Xue Bao; 2020 Feb; 36(2):320-331. PubMed ID: 32148004
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
